Cambria Investment Management’s AbbVie ABBV Stock Holding History

Cambria Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.98M	Buy	11,859 +4,725	+66%	+$1.02M	0.15%	168
2026 Q1	$1.55M	Sell	7,134 -487	-6%	-$108K	0.09%	181
2025 Q4	$1.74M	Buy	7,621 +4,473	+142%	+$1.02M	0.1%	185
2025 Q3	$729K	Buy	+3,148	New	+$641K	0.04%	270
2015 Q4	–	Sell	-154	Closed	-$8K	–	150
2015 Q3	$8K	Buy	+154	New	+$10K	﹤0.01%	294

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cambria Investment Management's ABBV Position: Q2 2026 in Review

Cambria Investment Management increased its AbbVie (ABBV) stake by 66% in Q2 2026, buying an estimated $1.02M and bringing the position to 11,859 shares worth $2.98M. The position accounts for 0.15% of the portfolio, ranked #168.

Cambria Investment Management first reported a position in ABBV in Q3 2015 and has held it in 5 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Cambria Investment Management held 11,859 shares of AbbVie worth $2.98M as of Q2 2026.
Cambria Investment Management bought 4,725 AbbVie shares in Q2 2026, an estimated $1.02M.
AbbVie made up 0.15% of Cambria Investment Management's portfolio in Q2 2026, its #168 holding.
Cambria Investment Management first reported a position in AbbVie in Q3 2015 and has held it in 5 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.